Enhancing stereotactic ablative boost radiotherapy dose prediction for bulky lung cancer: A multi-scale dilated network approach with scale-balanced structure loss.

PURPOSE

Partial stereotactic ablative boost radiotherapy (P-SABR) effectively treats bulky lung cancer; however, the planning process for P-SABR requires repeated dose calculations. To improve planning efficiency, we proposed a novel deep learning method that utilizes limited data to accurately predict the three-dimensional (3D) dose distribution of the P-SABR plan for bulky lung cancer.

METHODS

We utilized data on 74 patients diagnosed with bulky lung cancer who received P-SABR treatment. The patient dataset was randomly divided into a training set (51 plans) with augmentation, validation set (7 plans), and testing set (16 plans). We devised a 3D multi-scale dilated network (MD-Net) and integrated a scale-balanced structure loss into the loss function. A comparative analysis with a classical network and other advanced networks with multi-scale analysis capabilities and other loss functions was conducted based on the dose distributions in terms of the axial view, average dose scores (ADSs), and average absolute differences of dosimetric indices (AADDIs). Finally, we analyzed the predicted dosimetric indices against the ground-truth values and compared the predicted dose-volume histogram (DVH) with the ground-truth DVH.

RESULTS

Our proposed dose prediction method for P-SABR plans for bulky lung cancer demonstrated strong performance, exhibiting a significant improvement in predicting multiple indicators of regions of interest (ROIs), particularly the gross target volume (GTV). Our network demonstrated increased accuracy in most dosimetric indices and dose scores in different ROIs. The proposed loss function significantly enhanced the predictive performance of the dosimetric indices. The predicted dosimetric indices and DVHs were equivalent to the ground-truth values.

CONCLUSION

Our study presents an effective model based on limited datasets, and it exhibits high accuracy in the dose prediction of P-SABR plans for bulky lung cancer. This method has potential as an automated tool for P-SABR planning and can help optimize treatments and improve planning efficiency.